Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
111In-Panitumumab for Nodal Staging in Head and Neck Cancer
NCT04840472Phase 1Suspended
- Sponsor
- Stanford University
- Start
- Mar 2021
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 111In-panitumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Stanford University. Primary endpoint: Safety of 111In panitumumab at 15 days. Started Mar 2021; status: suspended.
02
Drugs
111In-panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04840472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840472.